Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Booster RT in Metastatic Pancreatic Cancer
NCT03490760Phase 2Terminated
- Sponsor
- Baptist Health South Florida
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in pancreatic adenocarcinoma (PDAC), sponsored by Baptist Health South Florida. Started Nov 2018; status: terminated.
02
Drugs
durvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03490760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490760.